275 results about "Hyperuricemia" patented technology

The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention discloses a fungus extract capable of effectively regulating uric acid metabolism and relieving inflammation as well as a preparation method and application of the fungus extract, and belongs to the technical field of deep processing of edible fungi. Schizophyllumcommuneh and poplar phellinus sporocarp are mixed and extracted, and the prepared fungus extract can effectively inhibit activity of xanthine oxidase in serum and liver of mice, reduce content of uric acid, creatinine, urea nitrogen and the like in serum and promote excretion of uric acid, creatinine, urea nitrogen and the like in urine; meanwhile, the content of inflammatory markers such as IL-6 and TNF-alpha in mouse serum can be effectively reduced, inflammatory infiltration of liver and kidney cells is relieved, and the problem that an existing edible mushroom extract is not ideal in treatment effect on hyperuricemia is solved.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

The invention relates to an application of sea cucumber intestine polysaccharide in preparation of uric acid lowering drugs. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.

The present invention discloses a humanized human-porcine chimeric uricase chimeric mutant. The amino acid sequence of the mutant is shown in SEQ ID NO. 1. The mutant has excellent uric acid level reduction and high homology with human uricase, providing a new option for drug treatment of hyperuricemia.

The invention belongs to the technical field of biological medicine, and relates to application of galangal polysaccharide in preparation of a preparation for improving intestinal flora imbalance. The galangal polysaccharide provided by the invention can effectively improve the alteration of intestinal flora, especially improve the alteration of intestinal flora induced by hyperuricemia, the hyperuricemia can cause intestinal barrier injury, then the intestinal flora is translocated to induce the alteration of the intestinal flora, and the galangal polysaccharide can up-regulate Occludin and ZO-1, repair the intestinal barrier injury and improve the integrity of the intestinal tract; after the action of the galangal polysaccharide, the influence on the intra-group diversity Beta diversity of the flora is large, the flora structure deviation caused by hypeluricemia can be reversed, and the intestinal flora structure deviation can be relieved. The galangal polysaccharide provided by the invention is a potential novel prebiotic, has an excellent effect in improving intestinal flora imbalance, and has a good application prospect.

The invention provides a strain of fermentation lactobacillus mucus TG017, and the strain of fermentation lactobacillus mucus TG017 has the effects of reducing uric acid, purine and adenosine. The lactobacillus fermentum is lactobacillus fermentum TG017, is preserved in the China Center for Type Culture Collection on April 10, 2023, has the preservation number of CCTCC NO: M 2023513, and is located in the preservation center of Wuhan University in Hubei China, and the preservation number of the lactobacillus fermentum TG017 is CCTCC NO: M 2023513. The invention further relates to the use of the Lactobacillus mucilaginosus TG017 strain.

The invention discloses a hexapeptide TE6 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide TE6 is TIATVE, and the hexapeptide TE6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide TE6 is identified from a solieria cavaleriei proteolysis solution and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 44.74%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; 0.05), which is stronger in xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The invention relates to the technical field of biology, and particularly discloses a strain with a uric acid reducing characteristic and a growth-dependent uric acid characteristic, and the microbial preservation number of the strain is GDMCC No.65914. The uric acid reducing strain is screened from pickles by a transparent ring method, the 16S rRNA gene sequence of the uric acid reducing strain is studied, a resource library of the uric acid reducing strain is expanded, resources are provided for research and development of uric acid reducing drugs in the clinical field, non-target strains are effectively removed through a dual specific screening mechanism of uric acid dependent growth verification and liquid fermentation induced uric acid reduction, and the yield of the uric acid reducing strains is increased. The uric acid reduction and uric acid dependence function stability and metabolic specificity of the screened strain are ensured, the high uric acid reduction strain obtained through screening can be directly used for developing a novel microecological preparation or a uric acid reduction preparation, and compared with traditional chemical drugs, the high uric acid reduction strain has the advantages of being high in safety, good in biocompatibility and small in side effect; high-quality strain resources are provided for biological treatment of hyperuricemia and gout and development of uric acid detection reagents.

The invention provides novel application and a method of asiaticoside. The method comprises the following steps: S1, extraction: taking a centella asiatica medicinal material, performing coarse crushing, adding ethanol, performing reflux extraction, performing filtration, and combining filtrate for standby application; s2, concentrating: concentrating the ethanol extracting solution under reduced pressure until no alcohol smell exists, centrifuging, and reserving supernate for later use; s3, carrying out D101 column chromatography; s4, alumina column chromatography; s5, performing concentration; s6, drying; s7, dissolving with methanol, adding water, standing, and monitoring clear liquid and crystallization conditions in a liquid phase; s8, filtering after crystallization is finished, washing with ethanol, drying crystals under the conditions that the vacuum degree is-0.06 to-0.08 mpa and the temperature is 60-70 DEG C, and crushing and sieving dry paste to obtain asiaticoside; specifically, the new application comprises reduction of uric acid (UA), urea (UREA), creatinine (CREZ), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (CHOL) in serum of a hyperuricemia model SD rat, and reduction of damage of hyperuricemia to kidney. And the yield of asiaticoside extracted by the method is high and is about 84%.

The invention discloses targeted prebiotic plant extraction dietary powder for relieving hyperuricemia and a preparation technology of the targeted prebiotic plant extraction dietary powder, and belongs to the technical field of dietary powder.In a formula of the targeted prebiotic plant extraction dietary powder for relieving hyperuricemia, as a patented bacterial strain, the bacillus coagulans MKSWC01 can directly act on the intestinal tract environment, uric acid precursor substances generated by purine metabolism are degraded in a targeted mode, and generation of uric acid is reduced from the source; the chicory root superfine powder and the mulberry leaf DNJ extract respectively activate kidney excretion protein, inhibit the activity of glycosidase, accelerate discharge of uric acid through urine and block the path of conversion from fructose metabolism to uric acid; the celery seed flavone and the smilax glabra polysaccharide further play an anti-inflammatory role, the deposition risk of urate crystals at joints is reduced, and potential inflammatory response caused by hyperuricemia is relieved. Meanwhile, the resistant dextrin and the xylooligosaccharide serve as prebiotics, nutrients are provided for probiotics to support planting of the probiotics, the overall metabolic environment can be improved by adjusting intestinal flora balance, the pathological link of hyperuricemia is comprehensively covered, and the relieving effect is improved.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.

The invention relates to the field of biological medicine, in particular to application of quercetagetin in preparation of medicine for preventing hyperuricemia and / or hyperuricemia related diseases. The invention discovers that quercetagetin has a prevention or improvement effect on hyperuricemia and related diseases for the first time. The result of the specific embodiment of the invention shows that the quercetagetin has a good uric acid reducing effect, obviously reduces the activity of uric acid generation participating enzyme, regulates the expression of uric acid transporter mRNA, improves liver injury and kidney injury caused by hyperuricemia, can prevent or relieve hyperuricemia or hyperuricemia-related diseases, and has a good application prospect. The composition can be used for preparing oral tablets and effervescent tablets.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The invention discloses a targeted screening method and application of a xanthine oxidase inhibitor in radix puerariae, and belongs to the technical field of medicinal chemistry. A surface chemical exchange method is carried out on xanthine oxidase through a ligand fishing technology, ligands of active groups of xanthine oxidase are modified to the surfaces of magnetic metal nanoparticles, the magnetic metal nanoparticles and a to-be-separated solution are incubated together, and then specific components with the xanthine oxidase inhibiting effect are successfully screened out through a UPLC-Q-TOF-MS / MS technology. The combination of the active component and the XOD active site is verified through molecular docking simulation to confirm that the active component is an effective inhibitor. The invention provides a reliable basis for further clinical research and development of drugs for treating hyperuricemia, and has a wide application prospect.

An Akk11 strain-containing probiotic agent capable of relieving hyperuricemia, and the use thereof. Strains in the probiotic agent include an Akkermansia muciniphila Akk11 strain and a Lactobacillus johnsonii LJ09 strain. It is found in the present application that the two strains possess a potential interaction and can cooperate with each other, thereby synergizing the effect of relieving hyperuricemia, which is specifically manifested in: being capable of remarkably regulating uric acid metabolism and improving renal clearance functions; being capable of effectively inhibiting the activity of a key enzyme for uric acid synthesis so as to reduce the production of uric acid, and being capable of remarkably relieving renal damage and renal dysfunctions associated with high levels of uric acid.

The invention relates to the technical field of medical informatics, in particular to an AI-based intelligent early warning system for hyperuricemia male reproductive metabolism abnormality. The system comprises a memory and a processor, and the processor executes a computer program stored in the memory to realize the following steps: acquiring uric acid data, waistline data, glycosylated hemoglobin data and reproductive index data of a target male; combining the uric acid fluctuation abnormality degree, the multi-dimensional blood glucose abnormality expression degree and the movement rule expression degree of each stage to obtain the reproduction metabolism abnormality degree; according to the relative relationship between the reproductive index data and the corresponding standard range, obtaining the abnormal performance degree of the reproductive index; integrating the reproductive metabolism abnormality degree and the reproductive index abnormality expression degree to obtain a multi-dimensional feature linkage reproductive metabolism expression comprehensive evaluation degree of the target male; and according to the comprehensive evaluation degree of the multi-dimensional feature linkage reproductive metabolism performance, whether early warning is carried out is judged. According to the invention, the accuracy and credibility of intelligent early warning of the risk of abnormal male reproductive metabolism of hyperuricemia are improved.

The invention discloses a small molecule peptide with xanthine oxidase inhibitory activity and application thereof, and belongs to the technical field of bioactive peptides. The amino acid sequence of the small molecule peptide with xanthine oxidase inhibitory activity is YDWRPF, and is as shown in SEQ ID NO. 8. The small molecule peptide with the xanthine oxidase inhibitory activity is applied to preparation of a xanthine oxidase inhibitor. The small molecule peptide YDWRPF is high in xanthine oxidase inhibitory activity, IC50 is only 2.73 + / -0.20 mM, and the small molecule peptide YDWRPF can be used as a raw material to prepare a xanthine oxidase inhibitor. The invention is of great significance to the treatment of hyperuricemia.

The application discloses a composition for protecting liver and strengthening kidney and reducing uric acid, which is made of the following raw material components: Anoectochilus roxburghii, dried tangerine or orange peel, chicory, gardenia, turmeric, Hovenia dulcis Thunb, Cistanche deserticola Y.C.Ma, Rehmannia glutinosa, potassium citrate, sodium citrate and goose myo-peptide. The composition combines the immortal concept of TCM (Traditional Chinese Medicine) "treating disease from the root" and the uric acid control method of modern nutritional medicine as an organic whole, and achieves multiple effects of protecting liver and strengthening kidney, mutual benefit of yin and yang and reducing uric acid through multiple action targets. Animal experiment results show that the composition can effectively reduce the activities of transaminase ALT and AST, relieve liver damage, reduce serum creatinine level and improve urea ammonia excretion rate, improve kidney function, inhibit the activities of xanthine oxidase and adenosine dehydrogenase and reduce uric acid level. The composition is safe and has no toxic side effects, is suitable for people with insufficient liver and kidney functions and hyperuricemia and has a wide application prospect.

The invention provides a hyperuricemia high-risk screening system and method based on big data, and relates to the technical field of big data deep learning, and the method comprises the steps: collecting feature data related to hyperuricemia from a plurality of data sources, carrying out the data preprocessing, calculating a related feature index based on the preprocessed data, and building a convolutional neural network model, thereby achieving the high-risk screening of hyperuricemia. The method comprises the following steps: inputting a feature index, outputting a hyperuricemia risk level, then obtaining feature data of a person to be screened, inputting a trained model, generating a risk level correction coefficient in combination with personal information, and finally determining a final hyperuricemia risk level index by setting an upgrading and degrading mechanism and comparing the correction coefficient with a preset threshold value. According to the method, feature data related to hyperuricemia are collected through multiple data sources, and accurate assessment of the hyperuricemia risk is realized in combination with the convolutional neural network model.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus reuteri JNL0037 and application thereof. The invention provides lactobacillus reuteri JNL0037, which is preserved in the China General Microbiological Culture Collection Center on December 27, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO: 33218. The lactobacillus reuteri JNL0037 can be used for preparing the lactobacillus reuteri JNL0037. The Lactobacillus reuteri JNL0037 provided by the invention has nucleoside degradation, anti-inflammatory and bacteriostatic capabilities, can be used for preparing drugs for treating hyperuricemia, gout and uric acid nephropathy, has extremely high development value and practical value, and provides a new idea for development and application of related products.

The invention discloses a quality detection method of a gout clearing mixture for treating hyperuricemia, which adopts a separation analysis technology of ultra-high performance liquid chromatography to detect eight chemical components in the gout clearing mixture. Comprising the following components: 3-O-feruloylquinic acid, 5-O-caffeoylshikimic acid, paeoniflorin, polydatin, neoastilbin, astilbin, berberine hydrochloride and emodin-8-beta-D-glucopyranoside. According to the method, eight chemical components of six active components in the gout clearing mixture are quantitatively analyzed at the same time, and the method has the advantages of being easy and convenient to operate, good in stability and easy to popularize. The invention can provide a comprehensive and reliable quality control basis for the gout clearing mixture, and has important significance for ensuring the clinical curative effect of the gout clearing mixture.

The invention discloses application of benzofuran components in eupatorium chinense to reduction of uric acid, compounds 1-3 are obtained by being separated from an eupatorium chinense extract, and the compound 1 is a new compound. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, HW-40F gel column chromatography, high performance liquid chromatography and other methods to obtain the benzofuran compound. According to the present invention, the inhibition activity of the gout disease related target xanthine oxidase of the separated compound 1-3 is tested, the experimental result shows that the compound 1-3 has good inhibition activity on the xanthine oxidase, and the molecular docking experiment shows that the compound 1-3 has good binding energy with the target protein. Therefore, the compounds 1-3 can be used for preparing a natural lead compound for delaying or treating diseases caused by xanthine oxidase and providing a natural lead compound in the field of treatment of hyperuricemia and gout.

To provide development of health food supplements and antioxidants for controlling hyperuricemia and oxidative stress.SOLUTION: Embodiments of the disclosure include methods and compositions that comprise one or more herb extracts and optionally folic acid and / or one or more of its derivatives. In specific embodiments, the disclosure concerns treatment or prevention of hyperuricemic conditions with combinatorial compositions, such as those including one or more Chinese herbal medicine extracts and optionally folic acid and / or one or more of its derivatives.SELECTED DRAWING: None

This invention discloses the XO-inhibiting peptide GDEY and its applications, belonging to the field of bioactive peptide technology. The amino acid sequence of the XO-inhibiting peptide GDEY is shown in SEQ ID NO.2. The invention also discloses the application of the XO-inhibiting peptide GDEY in the preparation of xanthine oxidase inhibitors and in the preparation of drugs with the effect of inhibiting uric acid levels. This invention used molecular docking and BLAST+ software to virtually screen 15 potential XO-inhibiting peptides from the complete protein sequence of Litopenaeus vannamei. High-performance liquid chromatography (HPLC) was used to determine the XO-inhibiting activity, and the results showed that 7 small molecule peptides exhibited significant XO-inhibiting activity, possessing potential value in preventing hyperuricemia.

This invention discloses a benzofuran compound and its application in lowering uric acid activity. Compounds 1-3 were isolated from the fermentation products of the endophytic fungus *Septoriella phragmitis*, with compound 1 being a novel compound. The fermentation products were purified using mixed solvent extraction, normal silica gel column chromatography, and high-performance liquid chromatography to obtain compounds 1-3. The inhibitory activity of compounds 1-3 on xanthine oxidase, a target related to gout symptoms, was tested. Experimental results showed that the novel compound 1 exhibited good inhibitory activity against xanthine oxidase. Molecular docking experiments also demonstrated that compound 1 had a good binding energy to the target protein. Therefore, compound 1 can be used to prepare a natural lead compound for delaying or treating diseases caused by xanthine oxidase, providing a potential therapeutic agent for hyperuricemia and gout.